| scholarly article | Q13442814 |
| P2093 | author name string | Saroj P Mathupala | |
| Young H Ko | |||
| Peter L Pedersen | |||
| P2860 | cites work | Glucose catabolism in cancer cells. The type II hexokinase promoter contains functionally active response elements for the tumor suppressor p53 | Q24308421 |
| Hexokinase II detachment from mitochondria triggers apoptosis through the permeability transition pore independent of voltage-dependent anion channels | Q24312702 | ||
| High aerobic glycolysis of rat hepatoma cells in culture: Role of mitochondrial hexokinase | Q24561487 | ||
| Hexokinase II: cancer's double-edged sword acting as both facilitator and gatekeeper of malignancy when bound to mitochondria | Q24595940 | ||
| Dichloroacetate (DCA) as a potential metabolic-targeting therapy for cancer | Q24652941 | ||
| Glucose catabolism in cancer cells. Isolation, sequence, and activity of the promoter for type II hexokinase | Q28115329 | ||
| Warburg, me and Hexokinase 2: Multiple discoveries of key molecular events underlying one of cancers' most common phenotypes, the "Warburg Effect", i.e., elevated glycolysis in the presence of oxygen | Q28249524 | ||
| A mitochondria-K+ channel axis is suppressed in cancer and its normalization promotes apoptosis and inhibits cancer growth | Q28283339 | ||
| Metabolic remodeling of malignant gliomas for enhanced sensitization during radiotherapy: an in vitro study | Q28286868 | ||
| Lactate and malignant tumors: a therapeutic target at the end stage of glycolysis | Q28292657 | ||
| Voltage-dependent anion channels are dispensable for mitochondrial-dependent cell death | Q28297152 | ||
| Inhibition of early apoptotic events by Akt/PKB is dependent on the first committed step of glycolysis and mitochondrial hexokinase | Q28366319 | ||
| Functional organization of mammalian hexokinases: both N- and C-terminal halves of the rat type II isozyme possess catalytic sites | Q28569739 | ||
| Hexokinase-mitochondria interaction mediated by Akt is required to inhibit apoptosis in the presence or absence of Bax and Bak | Q28572925 | ||
| The M2 splice isoform of pyruvate kinase is important for cancer metabolism and tumour growth | Q29547680 | ||
| Akt stimulates aerobic glycolysis in cancer cells | Q29619301 | ||
| Attenuation of LDH-A expression uncovers a link between glycolysis, mitochondrial physiology, and tumor maintenance | Q29620462 | ||
| Isozymes of mammalian hexokinase: structure, subcellular localization and metabolic function | Q33966115 | ||
| Rat glucokinase gene: structure and regulation by insulin | Q34284810 | ||
| Advanced cancers: eradication in all cases using 3-bromopyruvate therapy to deplete ATP. | Q34355664 | ||
| Silencing of monocarboxylate transporters via small interfering ribonucleic acid inhibits glycolysis and induces cell death in malignant glioma: an in vitro study | Q34372604 | ||
| Glucose catabolism in the rabbit VX2 tumor model for liver cancer: characterization and targeting hexokinase | Q34517998 | ||
| Mitochondrial hexokinases, novel mediators of the antiapoptotic effects of growth factors and Akt. | Q34554825 | ||
| Hexokinase II: the integration of energy metabolism and control of apoptosis | Q35181296 | ||
| Tumor Mitochondria and the Bioenergetics of Cancer Cells | Q35681852 | ||
| Akt-dependent transformation: there is more to growth than just surviving | Q36313173 | ||
| Mitochondriotoxic compounds for cancer therapy | Q36558020 | ||
| FDG-PET for evaluating the antitumor effect of intraarterial 3-bromopyruvate administration in a rabbit VX2 liver tumor model | Q37063643 | ||
| Causes and consequences of increased glucose metabolism of cancers | Q37181519 | ||
| Functional organization of mammalian hexokinase II. Retention of catalytic and regulatory functions in both the NH2- and COOH-terminal halves | Q38362603 | ||
| The role of mitochondrial hexokinase binding in the abnormal energy metabolism of tumor cell lines | Q39767160 | ||
| Hexokinases | Q40610320 | ||
| Glucose metabolism in cancer. Evidence that demethylation events play a role in activating type II hexokinase gene expression | Q40672976 | ||
| Glucose catabolism in cancer cells: amplification of the gene encoding type II hexokinase | Q41196274 | ||
| Glucose catabolism in cancer cells: regulation of the Type II hexokinase promoter by glucose and cyclic AMP. | Q41199416 | ||
| Intracellular pH governs the subcellular distribution of hexokinase in a glioma cell line | Q41234619 | ||
| An introduction to the isoenzymes of mammalian hexokinase types I-III. | Q41370047 | ||
| Microheterogeneity of cytosolic and membrane-bound hexokinase II in Morris hepatoma 3924A. | Q41437622 | ||
| Glucose catabolism in cancer cells: identification and characterization of a marked activation response of the type II hexokinase gene to hypoxic conditions | Q43738168 | ||
| The glycolytic phenotype in carcinogenesis and tumor invasion: insights through mathematical models | Q44521050 | ||
| Glucose metabolism in cancer: importance of transcription factor-DNA interactions within a short segment of the proximal region og the type II hexokinase promoter | Q44534309 | ||
| Functional significance of mitochondrial bound hexokinase in tumor cell metabolism. Evidence for preferential phosphorylation of glucose by intramitochondrially generated ATP. | Q44808698 | ||
| Mitochondrial hexokinases: guardians of the mitochondria | Q46450383 | ||
| Distinct domains of Bcl-XL are involved in Bax and Bad antagonism and in apoptosis inhibition | Q46629743 | ||
| Methyl jasmonate binds to and detaches mitochondria-bound hexokinase | Q46647628 | ||
| Synergistic antipancreatic tumor effect by simultaneously targeting hypoxic cancer cells with HSP90 inhibitor and glycolysis inhibitor | Q46696439 | ||
| Glucose utilization of cerebral gliomas measured by [18F] fluorodeoxyglucose and positron emission tomography | Q48867303 | ||
| Differences in expression and intracellular distribution of hexokinase isoenzymes in rat liver cells of different transformation stages | Q53468761 | ||
| Regulation of hexokinase in cultured gliomas. | Q55488040 | ||
| Positron emission tomographic study of suppression of gray-matter glucose utilization by brain tumors | Q55489310 | ||
| Mitochondrial hexokinase from differentiated and undifferentiated HT29 colon cancer cells: effect of some metabolites on the bound/soluble equilibrium | Q68781317 | ||
| Hexokinase receptor complex in hepatoma mitochondria: evidence from N,N'-dicyclohexylcarbodiimide-labeling studies for the involvement of the pore-forming protein VDAC | Q70136917 | ||
| Energy metabolism of tumor cells. Requirement for a form of hexokinase with a propensity for mitochondrial binding | Q70875496 | ||
| Mitochondrial hexokinase of rat hepatoma cells in culture: solubilization and kinetic properties | Q71532020 | ||
| Functional organization of mammalian hexokinases: characterization of chimeric hexokinases constructed from the N- and C-terminal domains of the rat type I and type II isozymes | Q72493997 | ||
| Functional organization of mammalian hexokinases: characterization of the rat type III isozyme and its chimeric forms, constructed with the N- and C-terminal halves of the type I and type II isozymes | Q73063748 | ||
| Clotrimazole and bifonazole detach hexokinase from mitochondria of melanoma cells | Q74449681 | ||
| Mitochondrial bound type II hexokinase: a key player in the growth and survival of many cancers and an ideal prospect for therapeutic intervention | Q74703072 | ||
| Evidence that transcription of the hexokinase gene is increased in a rapidly growing rat hepatoma | Q93669416 | ||
| P433 | issue | 1 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | mitochondrion | Q39572 |
| P304 | page(s) | 17-24 | |
| P577 | publication date | 2009-02-01 | |
| P13046 | publication type of scholarly work | review article | Q7318358 |
| P1433 | published in | Seminars in Cancer Biology | Q1908668 |
| P1476 | title | Hexokinase-2 bound to mitochondria: cancer's stygian link to the "Warburg Effect" and a pivotal target for effective therapy | |
| P478 | volume | 19 |
| Q37256225 | (18)F-FDG PET/CT for Monitoring the Response of Breast Cancer to miR-143-Based Therapeutics by Targeting Tumor Glycolysis |
| Q37640218 | 18F-FDG PET/CT as a predictor of hereditary head and neck paragangliomas |
| Q54526090 | 3-bromopyruvate (3BP) a fast acting, promising, powerful, specific, and effective “small molecule” anti-cancer agent taken from labside to bedside: introduction to a special issue |
| Q44176675 | 3-bromopyruvate inhibits glycolysis, depletes cellular glutathione, and compromises the viability of cultured primary rat astrocytes. |
| Q37980697 | 3-bromopyruvate: Targets and outcomes |
| Q24650249 | A new view of carcinogenesis and an alternative approach to cancer therapy |
| Q35931759 | A novel miR-155/miR-143 cascade controls glycolysis by regulatinghexokinase 2in breast cancer cells |
| Q39653310 | A translational study “case report” on the small molecule “energy blocker” 3-bromopyruvate (3BP) as a potent anticancer agent: from bench side to bedside |
| Q93081050 | Accelerated Metabolite Levels of Aerobic Glycolysis and the Pentose Phosphate Pathway Are Required for Efficient Replication of Infectious Spleen and Kidney Necrosis Virus in Chinese Perch Brain Cells |
| Q37643752 | Activity of hexokinase is increased by its interaction with hepatitis C virus protein NS5A. |
| Q39408732 | Adseverin: A novel cisplatin‐resistant marker in the human bladder cancer cell line HT1376 identified by quantitative proteomic analysis |
| Q37099704 | Akt Phosphorylates HK-II at Thr-473 and Increases Mitochondrial HK-II Association to Protect Cardiomyocytes |
| Q36452381 | Anticancer Agents That Counteract Tumor Glycolysis |
| Q64996377 | Anticancer effect of ursolic acid via mitochondria-dependent pathways. |
| Q38973075 | Association of cancer metabolism-related proteins with oral carcinogenesis - indications for chemoprevention and metabolic sensitizing of oral squamous cell carcinoma? |
| Q54414564 | Association of overexpression of hexokinase II with chemoresistance in epithelial ovarian cancer |
| Q55279249 | B cell lymphoma with different metabolic characteristics show distinct sensitivities to metabolic inhibitors. |
| Q64070924 | B7-H3 promotes aerobic glycolysis and chemoresistance in colorectal cancer cells by regulating HK2 |
| Q33882790 | BRCA1 induces major energetic metabolism reprogramming in breast cancer cells. |
| Q33587154 | Benserazide, a dopadecarboxylase inhibitor, suppresses tumor growth by targeting hexokinase 2. |
| Q39031431 | Bioenergetic modulation overcomes glucocorticoid resistance in T-lineage acute lymphoblastic leukaemia |
| Q34210845 | Biomarker signatures of mitochondrial NDUFS3 in invasive breast carcinoma |
| Q39428665 | Bone marrow adipocytes promote the Warburg phenotype in metastatic prostate tumors via HIF-1α activation |
| Q55317070 | Cancer and Exercise: Warburg Hypothesis, Tumour Metabolism and High-Intensity Anaerobic Exercise. |
| Q38046274 | Cancer cell metabolism: one hallmark, many faces. |
| Q39290930 | Cancer: a de-repression of a default survival program common to all cells?: a life-history perspective on the nature of cancer |
| Q47949426 | Changes in the mitochondrial function and in the efficiency of energy transfer pathways during cardiomyocyte aging |
| Q34447257 | Choline kinase alpha and hexokinase-2 protein expression in hepatocellular carcinoma: association with survival |
| Q37713441 | Chrysin inhibited tumor glycolysis and induced apoptosis in hepatocellular carcinoma by targeting hexokinase-2. |
| Q47559179 | Clear cell hepatocellular carcinoma: origin, metabolic traits and fate of glycogenotic clear and ground glass cells |
| Q41629838 | Computational modeling of the metabolic States regulated by the kinase akt |
| Q33590969 | Current views on cell metabolism in SDHx-related pheochromocytoma and paraganglioma |
| Q42680803 | Decreased Brain pH as a Shared Endophenotype of Psychiatric Disorders. |
| Q39328727 | Decreased lactate concentration and glycolytic enzyme expression reflect inhibition of mTOR signal transduction pathway in B-cell lymphoma |
| Q33779169 | Deguelin inhibits non-small cell lung cancer via down-regulating Hexokinases II-mediated glycolysis |
| Q38085071 | Deregulation of glycolysis in cancer: glyceraldehyde-3-phosphate dehydrogenase as a therapeutic target |
| Q38182491 | Development of anticancer drugs based on the hallmarks of tumor cells. |
| Q38961504 | Dicer mediating the expression of miR-143 and miR-155 regulates hexokinase II associated cellular response to hypoxia |
| Q40786667 | Differential association of STAT3 and HK-II expression in hepatitis B virus- and hepatitis C virus-related hepatocellular carcinoma |
| Q34029401 | Differential gene expression profiling of human bone marrow-derived mesenchymal stem cells during adipogenic development |
| Q37530258 | Direct inhibition of hexokinase activity by metformin at least partially impairs glucose metabolism and tumor growth in experimental breast cancer |
| Q38785646 | Discovery of a Novel 2,6-Disubstituted Glucosamine Series of Potent and Selective Hexokinase 2 Inhibitors |
| Q90389852 | Dissociation of mitochondrial HK-II elicits mitophagy and confers cardioprotection against ischemia |
| Q38327525 | Dysregulated glycolysis as an oncogenic event |
| Q91750497 | Dysregulation of Glucose Metabolism by Oncogenes and Tumor Suppressors in Cancer Cells |
| Q28270014 | Dysregulation of glucose transport, glycolysis, TCA cycle and glutaminolysis by oncogenes and tumor suppressors in cancer cells |
| Q36342034 | EPR oxygen imaging and hyperpolarized 13C MRI of pyruvate metabolism as noninvasive biomarkers of tumor treatment response to a glycolysis inhibitor 3‐bromopyruvate |
| Q92245558 | Effect of IDH3a on glucose uptake in lung adenocarcinoma: A pilot study based on [18 F]FDG |
| Q36545216 | Effective impairment of myeloma cells and their progenitors by blockade of monocarboxylate transportation |
| Q41174750 | Effects of topoisomerase inhibitors that induce DNA damage response on glucose metabolism and PI3K/Akt/mTOR signaling in multiple myeloma cells. |
| Q38719175 | Effects on Energy Metabolism of Two Guanidine Molecules, (Boc)2 -Creatine and Metformin |
| Q97419057 | Emerging roles and the regulation of aerobic glycolysis in hepatocellular carcinoma |
| Q58724065 | Emerging roles of long non-coding RNAs in tumor metabolism |
| Q33940583 | Energy metabolism in human pluripotent stem cells and their differentiated counterparts |
| Q38943330 | Energy metabolism targeted drugs synergize with photodynamic therapy to potentiate breast cancer cell death |
| Q37874709 | Enzymatic features of the glucose metabolism in tumor cells |
| Q37699025 | Epigenetics and cancer metabolism |
| Q89617509 | Erastin-Like Anti-Warburg Agents Prevent Mitochondrial Depolarization Induced by Free Tubulin and Decrease Lactate Formation in Cancer Cells |
| Q50335966 | Expression and role in glycolysis of human ADP-dependent glucokinase |
| Q92523414 | FOXE1 represses cell proliferation and Warburg effect by inhibiting HK2 in colorectal cancer |
| Q37565352 | FOXM1 promotes reprogramming of glucose metabolism in epithelial ovarian cancer cells via activation of GLUT1 and HK2 transcription |
| Q96136313 | FOXO1 deficiency impairs proteostasis in aged T cells |
| Q42152592 | Facilitative glucose transporter Glut1 is actively excluded from rod outer segments. |
| Q58793764 | Fenbendazole acts as a moderate microtubule destabilizing agent and causes cancer cell death by modulating multiple cellular pathways |
| Q36515953 | Forward Chemical Genetics in Yeast for Discovery of Chemical Probes Targeting Metabolism |
| Q34440476 | Free Tubulin Modulates Mitochondrial Membrane Potential in Cancer Cells |
| Q50099421 | Friend virus limits adaptive cellular immune responses by imprinting a maturation-resistant and T helper type 2-biased immunophenotype in dendritic cells. |
| Q51069058 | From gametogenesis and stem cells to cancer: common metabolic themes. |
| Q50330006 | Functional Imaging Signature of Patients Presenting with Polycythemia/Paraganglioma Syndromes |
| Q37671201 | Glucose Metabolism Gene Variants Modulate the Risk of Pancreatic Cancer |
| Q91810115 | Glucose Transporter 3 is Essential for the Survival of Breast Cancer Cells in the Brain |
| Q37865165 | Glucose in platelet additive solutions: to add or not to add? |
| Q37620721 | Glucose metabolism and hexosamine pathway regulate oncogene-induced senescence. |
| Q37859317 | Glucose metabolism disorders and the risk of cancer. |
| Q37653931 | Glucose metabolism gene polymorphisms and clinical outcome in pancreatic cancer |
| Q26766098 | Glucose metabolism in gastric cancer: The cutting-edge |
| Q28477764 | Glycolysis Inhibition Inactivates ABC Transporters to Restore Drug Sensitivity in Malignant Cells |
| Q47128837 | Glycolysis and the Hexosamine Biosynthetic Pathway as Novel Targets for Upper and Lower Airway Inflammation |
| Q50504958 | Glycolysis in preimplantation development is partially controlled by the Warburg Effect. |
| Q35741135 | HK2 is a radiation resistant and independent negative prognostic factor for patients with locally advanced cervical squamous cell carcinoma |
| Q45760903 | HOTAIR regulates HK2 expression by binding endogenous miR-125 and miR-143 in oesophageal squamous cell carcinoma progression |
| Q47151726 | Hexokinase 2 (HK2), the tumor promoter in glioma, is downregulated by miR-218/Bmi1 pathway |
| Q37174905 | Hexokinase 2 is a determinant of neuroblastoma metastasis |
| Q41347851 | Hexokinase 2 promotes tumor growth and metastasis by regulating lactate production in pancreatic cancer |
| Q41380791 | Hexokinase I N-terminal based peptide prevents the VDAC1-SOD1 G93A interaction and re-establishes ALS cell viability. |
| Q33880100 | Hexokinase II inhibitor, 3-BrPA induced autophagy by stimulating ROS formation in human breast cancer cells |
| Q34924245 | Hexokinase II integrates energy metabolism and cellular protection: Akting on mitochondria and TORCing to autophagy |
| Q92236443 | Hexokinase II promotes the Warburg effect by phosphorylating alpha subunit of pyruvate dehydrogenase |
| Q33554640 | Hexokinase II-derived cell-penetrating peptide targets mitochondria and triggers apoptosis in cancer cells |
| Q37196742 | Hexokinase-2-mediated aerobic glycolysis is integral to cerebellar neurogenesis and pathogenesis of medulloblastoma |
| Q27011856 | How does the metabolism of tumour cells differ from that of normal cells |
| Q37287105 | Human Hepatocellular Carcinoma Metabolism: Imaging by Hyperpolarized (13)C Magnetic Resonance Spectroscopy. |
| Q88574458 | Including the mitochondrial metabolism of L-lactate in cancer metabolic reprogramming |
| Q33934809 | Induction of the Warburg effect by Kaposi's sarcoma herpesvirus is required for the maintenance of latently infected endothelial cells |
| Q38800149 | Inhibition of Lung Carcinoma A549 Cell Growth by Knockdown of Hexokinase 2 In Situ and In Vivo |
| Q26739857 | Insights into the Regulatory Role of Non-coding RNAs in Cancer Metabolism |
| Q34768395 | Insights into the pathogenesis and treatment of cancer from inborn errors of metabolism |
| Q59138361 | Intracellular Energy-Transfer Networks and High-Resolution Respirometry: A Convenient Approach for Studying Their Function |
| Q37720050 | Involvement of EZH2 in aerobic glycolysis of prostate cancer through miR-181b/HK2 axis |
| Q37615064 | Is p53 Involved in Tissue-Specific Insulin Resistance Formation? |
| Q41895412 | Ketolytic and glycolytic enzymatic expression profiles in malignant gliomas: implication for ketogenic diet therapy |
| Q57072208 | LINK-A promotes cell proliferation through the regulation of aerobic glycolysis in non-small-cell lung cancer |
| Q38351424 | Lactate as an insidious metabolite due to the Warburg effect |
| Q104132873 | LigGrep: a tool for filtering docked poses to improve virtual-screening hit rates |
| Q37739321 | Lipids, mitochondria and cell death: implications in neuro-oncology. |
| Q90291141 | LncRNA loc285194 inhibits tumor growth of laryngeal squamous cell carcinoma cells by downregulating hexokinase 2 |
| Q35788743 | Local delivery of cancer-cell glycolytic inhibitors in high-grade glioma |
| Q92889838 | Long non-coding RNA HOTAIR promotes cancer cell energy metabolism in pancreatic adenocarcinoma by upregulating hexokinase-2 |
| Q35051674 | Long non-coding RNA UCA1 promotes glycolysis by upregulating hexokinase 2 through the mTOR-STAT3/microRNA143 pathway |
| Q37438881 | MYC-induced cancer cell energy metabolism and therapeutic opportunities |
| Q37924658 | Mammalian NADH:ubiquinone oxidoreductase (Complex I) and nicotinamide nucleotide transhydrogenase (Nnt) together regulate the mitochondrial production of H2O2—Implications for their role in disease, especially cancer |
| Q38920583 | Mechanism of antineoplastic activity of lonidamine |
| Q47132544 | Mesenchymal stem cell conditioned medium alleviates oxidative stress injury induced by hydrogen peroxide via regulating miR143 and its target protein in hepatocytes |
| Q36137196 | Metabolic Plasticity in Cancer Cells: Reconnecting Mitochondrial Function to Cancer Control |
| Q90043554 | Metabolic Remodeling as a Way of Adapting to Tumor Microenvironment (TME), a Job of Several Holders |
| Q53697345 | Metabolic Reprogramming in Thyroid Carcinoma |
| Q64080628 | Metabolic alterations and the potential for targeting metabolic pathways in the treatment of multiple myeloma |
| Q39546982 | Metabolic oxidative stress elicited by the copper(II) complex [Cu(isaepy)2] triggers apoptosis in SH-SY5Y cells through the induction of the AMP-activated protein kinase/p38MAPK/p53 signalling axis: evidence for a combined use with 3-bromopyruvate i |
| Q47110867 | Metabolic remodeling in human colorectal cancer and surrounding tissues: alterations in regulation of mitochondrial respiration and metabolic fluxes |
| Q58566659 | Metabolic subtyping of pheochromocytoma and paraganglioma by F-FDG pharmacokinetics using dynamic PET/CT scanning |
| Q30540902 | Metformin impairs glucose consumption and survival in Calu-1 cells by direct inhibition of hexokinase-II. |
| Q39707409 | Metformin, independent of AMPK, inhibits mTORC1 in a rag GTPase-dependent manner |
| Q28658683 | Methyl jasmonate: putative mechanisms of action on cancer cells cycle, metabolism, and apoptosis |
| Q90665135 | MiR-125b-5p suppresses the bladder cancer progression via targeting HK2 and suppressing PI3K/AKT pathway |
| Q55057043 | MiR-199a-5p is negatively associated with malignancies and regulates glycolysis and lactate production by targeting hexokinase 2 in liver cancer. |
| Q36080463 | MicroRNA-143 (miR-143) Regulates Cancer Glycolysis via Targeting Hexokinase 2 Gene |
| Q41947674 | MicroRNA-143 acts as a tumor suppressor by targeting hexokinase 2 in human prostate cancer. |
| Q33775931 | MicroRNA-143 suppresses oral squamous cell carcinoma cell growth, invasion and glucose metabolism through targeting hexokinase 2. |
| Q36562171 | MicroRNA-29B (mir-29b) regulates the Warburg effect in ovarian cancer by targeting AKT2 and AKT3 |
| Q37535535 | Mitochondria and energetic depression in cell pathophysiology |
| Q36702313 | Mitochondrial NDUFS3 regulates the ROS-mediated onset of metabolic switch in transformed cells |
| Q34854255 | Mitochondrial approaches to protect against cardiac ischemia and reperfusion injury. |
| Q38201407 | Mitochondrial channels: ion fluxes and more |
| Q42436880 | Mitochondrial energetic and AKT status mediate metabolic effects and apoptosis of metformin in human leukemic cells. |
| Q37932441 | Mitochondrial metabolism inhibitors for cancer therapy. |
| Q33540676 | Mitochondrial mutations in hepatocellular carcinomas and fibrolamellar carcinomas |
| Q40501815 | Mitochondrial quality control: Cell-type-dependent responses to pathological mutant mitochondrial DNA |
| Q47286778 | Modulation of the Tumor Microenvironment by Epstein-Barr virus Latent Membrane Protein-1 in Nasopharyngeal Carcinoma. |
| Q83398609 | Molecular model of hexokinase binding to the outer mitochondrial membrane porin (VDAC1): Implication for the design of new cancer therapies |
| Q36329646 | NES1/KLK10 gene represses proliferation, enhances apoptosis and down-regulates glucose metabolism of PC3 prostate cancer cells |
| Q36703351 | Nanotechnology inspired tools for mitochondrial dysfunction related diseases |
| Q35913655 | Nkx3.1 and Myc crossregulate shared target genes in mouse and human prostate tumorigenesis |
| Q132041464 | Noncoding RNAs in the Glycolysis of Ovarian Cancer |
| Q93022612 | Novel mitochondrion-targeting copper(II) complex induces HK2 malfunction and inhibits glycolysis via Drp1-mediating mitophagy in HCC |
| Q38568602 | Novel roles and therapeutic targets of Epstein-Barr virus-encoded latent membrane protein 1-induced oncogenesis in nasopharyngeal carcinoma |
| Q37884056 | Novel ways to target brain tumour metabolism. |
| Q36683880 | Nuclear receptors and the Warburg effect in cancer |
| Q49386611 | Opening of voltage dependent anion channels promotes reactive oxygen species generation, mitochondrial dysfunction and cell death in cancer cells. |
| Q42535968 | Over-expression of GAPDH in human colorectal carcinoma as a preferred target of 3-Bromopyruvate Propyl Ester |
| Q39197536 | PET Radiomics in NSCLC: state of the art and a proposal for harmonization of methodology |
| Q35562841 | PGC-1-related Coactivator (PRC), a Sensor of Metabolic Stress, Orchestrates a Redox-sensitive Program of Inflammatory Gene Expression |
| Q35801521 | PPARγ contributes to PKM2 and HK2 expression in fatty liver |
| Q36682211 | Pathophysiological Consequences of TAT-HKII Peptide Administration Are Independent of Impaired Vascular Function and Ensuing Ischemia |
| Q40418483 | Phosphoglycerate mutase 1 promotes cancer cell migration independent of its metabolic activity |
| Q30234765 | Poor prognosis of hexokinase 2 overexpression in solid tumors of digestive system: a meta-analysis |
| Q33900808 | Posttranslational Modification of 6-phosphofructo-1-kinase as an Important Feature of Cancer Metabolism |
| Q34117168 | Potential therapeutic benefits of strategies directed to mitochondria. |
| Q36681329 | Prognostic PET 18F-FDG uptake imaging features are associated with major oncogenomic alterations in patients with resected non-small cell lung cancer |
| Q36185753 | Prognostic Significance of the Metabolic Marker Hexokinase-2 in Various Solid Tumors: A Meta-Analysis |
| Q26825585 | Protective effects and mechanisms of sirtuins in the nervous system |
| Q42643543 | Proteomic profiling of a layered tissue reveals unique glycolytic specializations of photoreceptor cells |
| Q36955054 | Re-programming tumour cell metabolism to treat cancer: no lone target for lonidamine |
| Q54502504 | Reduced hexokinase II impairs muscle function 2 wk after ischemia-reperfusion through increased cell necrosis and fibrosis |
| Q37520359 | Regulation of HK2 expression through alterations in CpG methylation of the HK2 promoter during progression of hepatocellular carcinoma |
| Q37492236 | Regulation of VDAC trafficking modulates cell death |
| Q37634341 | Regulation of glycolysis in head and neck squamous cell carcinoma. |
| Q26827829 | Regulation of mitochondrial function by voltage dependent anion channels in ethanol metabolism and the Warburg effect |
| Q39284220 | Repeated cisplatin treatment can lead to a multiresistant tumor cell population with stem cell features and sensitivity to 3-bromopyruvate. |
| Q28076454 | Reprogramming of glucose metabolism in hepatocellular carcinoma: Progress and prospects |
| Q83143509 | Respiratory competent mitochondria in human ovarian and peritoneal cancer |
| Q38732069 | Resveratrol inhibits Hexokinases II mediated glycolysis in non-small cell lung cancer via targeting Akt signaling pathway |
| Q39172136 | Role of Sp Transcription Factors in the Regulation of Cancer Cell Metabolism |
| Q47654911 | Role of hypoxia in Diffuse Large B-cell Lymphoma: Metabolic repression and selective translation of HK2 facilitates development of DLBCL. |
| Q64080005 | Roles of GLUT-1 and HK-II expression in the biological behavior of head and neck cancer |
| Q40236517 | STAT3 regulates glycolysis via targeting hexokinase 2 in hepatocellular carcinoma cells |
| Q54978483 | Salvanic acid B inhibits glycolysis in oral squamous cell carcinoma via targeting PI3K/AKT/HIF-1α signaling pathway. |
| Q42744255 | Screening the yeast genome for energetic metabolism pathways involved in a phenotypic response to the anti-cancer agent 3-bromopyruvate |
| Q85215635 | Separate and concurrent use of 2-deoxy-D-glucose and 3-bromopyruvate in pancreatic cancer cells |
| Q36270963 | Suppression of miR-199a maturation by HuR is crucial for hypoxia-induced glycolytic switch in hepatocellular carcinoma |
| Q34539146 | TP53 mutation hits energy metabolism and increases glycolysis in breast cancer |
| Q61796222 | Targeting Epidermal Growth Factor Receptor (EGFR) and Human Epidermal Growth Factor Receptor 2 (HER2) Expressing Bladder Cancer Using Combination Photoimmunotherapy (PIT) |
| Q38132274 | Targeting VDAC-bound hexokinase II: a promising approach for concomitant anti-cancer therapy |
| Q37983497 | Targeting aerobic glycolysis: 3-bromopyruvate as a promising anticancer drug |
| Q37924094 | Targeting cancer metabolism: a therapeutic window opens |
| Q35829696 | Targeting glycolysis by 3-bromopyruvate improves tamoxifen cytotoxicity of breast cancer cell lines |
| Q33699410 | Targeting hexokinase 2 inhibition promotes radiosensitization in HPV16 E7-induced cervical cancer and suppresses tumor growth. |
| Q37686277 | Targeting hexokinase II to mitochondria to modulate energy metabolism and reduce ischaemia-reperfusion injury in heart |
| Q44266484 | Targeting insulin inhibition as a metabolic therapy in advanced cancer: A pilot safety and feasibility dietary trial in 10 patients |
| Q38179992 | Targeting metabolism with a ketogenic diet during the treatment of glioblastoma multiforme |
| Q38264534 | Targeting mitochondrial function for the treatment of breast cancer. |
| Q90720782 | Targeting mitochondrial hexokinases increases efficacy of histone deacetylase inhibitors in solid tumor models |
| Q28073392 | The HK2 Dependent "Warburg Effect" and Mitochondrial Oxidative Phosphorylation in Cancer: Targets for Effective Therapy with 3-Bromopyruvate |
| Q57171912 | The Lipid Side of Bone Marrow Adipocytes: How Tumor Cells Adapt and Survive in Bone |
| Q90145439 | The Roles of HK2 on Tumorigenesis of Cervical Cancer |
| Q33504560 | The Warburg effect is genetically determined in inherited pheochromocytomas |
| Q36746415 | The anti-tumour agent lonidamine is a potent inhibitor of the mitochondrial pyruvate carrier and plasma membrane monocarboxylate transporters. |
| Q38837920 | The anticancer agent 3-bromopyruvate: a simple but powerful molecule taken from the lab to the bedside. |
| Q92354463 | The combination of the glycolysis inhibitor 2-DG and sorafenib can be effective against sorafenib-tolerant persister cancer cells |
| Q89584341 | The complexity of mitochondrial outer membrane permeability and VDAC regulation by associated proteins |
| Q54962531 | The decrease of glycolytic enzyme hexokinase 1 accelerates tumor malignancy via deregulating energy metabolism but sensitizes cancer cells to 2-deoxyglucose inhibition. |
| Q38612793 | The greedy nature of mutant RAS: a boon for drug discovery targeting cancer metabolism? |
| Q33779972 | The miR-125a/HK2 axis regulates cancer cell energy metabolism reprogramming in hepatocellular carcinoma |
| Q38245433 | The mitochondrial permeability transition: a current perspective on its identity and role in ischaemia/reperfusion injury. |
| Q37728362 | The pivotal roles of mitochondria in cancer: Warburg and beyond and encouraging prospects for effective therapies |
| Q28544747 | The reversal effects of 3-bromopyruvate on multidrug resistance in vitro and in vivo derived from human breast MCF-7/ADR cells |
| Q38247510 | The role of hexokinase in cardioprotection - mechanism and potential for translation |
| Q38248194 | The role of tubulin in the mitochondrial metabolism and arrangement in muscle cells. |
| Q38039421 | The scarlet letter of alkylation: a mini review of selective alkylating agents. |
| Q36619161 | Therapeutic Implications of Targeting Energy Metabolism in Breast Cancer |
| Q89638508 | Therapeutic targeting of YY1/MZF1 axis by MZF1-uPEP inhibits aerobic glycolysis and neuroblastoma progression |
| Q38025264 | Therapeutic targets in cancer cell metabolism and autophagy |
| Q35513668 | Thyroid hormone differentially modulates Warburg phenotype in breast cancer cells |
| Q62663288 | Transport and cytotoxicity of the anticancer drug 3-bromopyruvate in the yeast Saccharomyces cerevisiae |
| Q64097374 | Tubulin βII and βIII Isoforms as the Regulators of VDAC Channel Permeability in Health and Disease |
| Q64055907 | Tumor Energy Metabolism and Potential of 3-Bromopyruvate as an Inhibitor of Aerobic Glycolysis: Implications in Tumor Treatment |
| Q34179999 | Tumor bioenergetics: an emerging avenue for cancer metabolism targeted therapy |
| Q38168262 | Tumor glycolysis as a target for cancer therapy: progress and prospects |
| Q50105551 | Up-regulation of hexokinase II contributes to rituximab-chemotherapy resistance and is a clinically relevant target for therapeutic development. |
| Q39402922 | Up-regulation of hexokinaseII in myeloma cells: targeting myeloma cells with 3-bromopyruvate |
| Q38734054 | Uptake and Toxicity of Copper Oxide Nanoparticles in C6 Glioma Cells. |
| Q90443126 | VDAC1 at the crossroads of cell metabolism, apoptosis and cell stress |
| Q37211985 | VDAC1-based peptides: novel pro-apoptotic agents and potential therapeutics for B-cell chronic lymphocytic leukemia |
| Q42219057 | Voltage dependent anion channel-1 (VDAC-1) as an anti-cancer target |
| Q41173095 | Voltage-Dependent Anion Channel 1 As an Emerging Drug Target for Novel Anti-Cancer Therapeutics |
| Q36796837 | Voltage-dependent anion channels modulate mitochondrial metabolism in cancer cells: regulation by free tubulin and erastin |
| Q24313608 | Warburg effect revisited: an epigenetic link between glycolysis and gastric carcinogenesis |
| Q28072714 | Warburg effect, hexokinase-II, and radioresistance of laryngeal carcinoma |
| Q36065049 | Warburg-like Glycolysis and Lactate Shuttle in Mouse Decidua during Early Pregnancy |
| Q26859261 | What is good for the circulation also lessens cancer risk |
| Q35599322 | White spot syndrome virus induces metabolic changes resembling the warburg effect in shrimp hemocytes in the early stage of infection |
| Q31120020 | Zinc finger nuclease mediated knockout of ADP-dependent glucokinase in cancer cell lines: effects on cell survival and mitochondrial oxidative metabolism |
| Q92229053 | [13C6,D8]2-deoxyglucose phosphorylation by hexokinase shows selectivity for the β-anomer |
| Q36874412 | mTORC1-Induced HK1-Dependent Glycolysis Regulates NLRP3 Inflammasome Activation. |
| Q42371270 | miR-125a suppresses viability and glycolysis and induces apoptosis by targeting Hexokinase 2 in laryngeal squamous cell carcinoma |
| Q39370392 | miR-143 regulates hexokinase 2 expression in cancer cells |
| Q90480858 | miR-202 functions as a tumor suppressor in hepatocellular carcinoma by targeting HK2 |
| Q90719437 | miR-885-5p Negatively Regulates Warburg Effect by Silencing Hexokinase 2 in Liver Cancer |
| Q38100489 | miRNAs link metabolic reprogramming to oncogenesis |
| Q28292014 | p53-dependent anticancer effects of leptomycin B on lung adenocarcinoma |
Search more.